Delcath Systems Stock

Delcath Systems Forward P/E

The Forward P/E Ratio of Delcath Systems (DCTH) as of Aug 8, 2026 is 121.77. In the previous year, Forward P/E Ratio was -12.46 — a change of -1,077.26% (higher).

Forward P/E

121.77

YoY

-1,077.26%

Last updated:

Forward P/E Ratio of Delcath Systems is 2026 121.77 . Forward P/E Ratio of Delcath Systems was 2025 -12.46 . It decreases by -1,077.26% higher compared to the previous year.
Access this data via the Eulerpool API

Delcath Systems Stock analysis

What does Delcath Systems do? Delcath Systems Inc is a US-American medical technology company specializing in the development of innovative products for the treatment of various forms of liver cancer. The company was founded in 1988 in New York and is headquartered in Queensbury today. Delcath Systems is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Delcath Systems stock

Forward P/E Ratio of Delcath Systems is 121.77 in 2026.

Forward P/E Ratio of Delcath Systems changed from -12.46 to 121.77, representing a -1,077.26% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Delcath Systems since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Delcath Systems with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Delcath Systems

All Key Metrics — Delcath Systems